Transgene and NEC report 100% three-year disease-free survival
Transgene (TNG) and NEC (6701) said they report 100% three-year disease-free survival with TG4050 and plan to publish Phase 1 results in Nature Communications.
Tokyo, Japan and Strasbourg, France, Sept 8, 2026 - (JCN Newswire) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, today report…